Heart attack survivors: new hope from Cholesterol-Lowering drug?
NCT ID NCT06740552
First seen Feb 02, 2026 · Last updated May 08, 2026 · Updated 13 times
Summary
This study looked at whether evolocumab, a cholesterol-lowering drug, can reduce the risk of major heart problems in people who had a heart attack and have blockages in multiple heart arteries. Researchers analyzed data from 1,862 patients to see if the drug lowers the chance of another heart attack, heart failure, or heart-related death. The goal is to find better ways to manage heart disease long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYOCARDIAL INFARCTION (AMI) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200000, China
Conditions
Explore the condition pages connected to this study.